Table of Content

1 Report Overview
1.1 Leiomyosarcoma Drug Definition
1.2 Market by Type
1.2.1 Global Leiomyosarcoma Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 AL-3818
1.2.3 BGB-290
1.2.4 C-21
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Leiomyosarcoma Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Leiomyosarcoma Drug Sales
2.1 Global Leiomyosarcoma Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Leiomyosarcoma Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Leiomyosarcoma Drug Revenue by Region
2.3.1 Global Leiomyosarcoma Drug Revenue by Region (2018-2023)
2.3.2 Global Leiomyosarcoma Drug Revenue by Region (2024-2034)
2.4 Global Leiomyosarcoma Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Leiomyosarcoma Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Leiomyosarcoma Drug Sales Quantity by Region
2.6.1 Global Leiomyosarcoma Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Leiomyosarcoma Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Leiomyosarcoma Drug Sales Quantity by Manufacturers
3.1.1 Global Leiomyosarcoma Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Leiomyosarcoma Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Leiomyosarcoma Drug Sales in 2024
3.2 Global Leiomyosarcoma Drug Revenue by Manufacturers
3.2.1 Global Leiomyosarcoma Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Leiomyosarcoma Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Leiomyosarcoma Drug Revenue in 2024
3.3 Global Leiomyosarcoma Drug Sales Price by Manufacturers
3.4 Global Key Players of Leiomyosarcoma Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Leiomyosarcoma Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Leiomyosarcoma Drug, Product Offered and Application
3.8 Global Key Manufacturers of Leiomyosarcoma Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Leiomyosarcoma Drug Sales Quantity by Type
4.1.1 Global Leiomyosarcoma Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Leiomyosarcoma Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Leiomyosarcoma Drug Revenue by Type
4.2.1 Global Leiomyosarcoma Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Leiomyosarcoma Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
4.3 Global Leiomyosarcoma Drug Price by Type
4.3.1 Global Leiomyosarcoma Drug Price by Type (2018-2023)
4.3.2 Global Leiomyosarcoma Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Leiomyosarcoma Drug Sales Quantity by Application
5.1.1 Global Leiomyosarcoma Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Leiomyosarcoma Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Leiomyosarcoma Drug Revenue by Application
5.2.1 Global Leiomyosarcoma Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Leiomyosarcoma Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
5.3 Global Leiomyosarcoma Drug Price by Application
5.3.1 Global Leiomyosarcoma Drug Price by Application (2018-2023)
5.3.2 Global Leiomyosarcoma Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Leiomyosarcoma Drug Sales by Company
6.1.1 North America Leiomyosarcoma Drug Revenue by Company (2018-2023)
6.1.2 North America Leiomyosarcoma Drug Sales Quantity by Company (2018-2023)
6.2 North America Leiomyosarcoma Drug Market Size by Type
6.2.1 North America Leiomyosarcoma Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Leiomyosarcoma Drug Revenue by Type (2018-2034)
6.3 North America Leiomyosarcoma Drug Market Size by Application
6.3.1 North America Leiomyosarcoma Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Leiomyosarcoma Drug Revenue by Application (2018-2034)
6.4 North America Leiomyosarcoma Drug Market Size by Country
6.4.1 North America Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Leiomyosarcoma Drug Revenue by Country (2018-2034)
6.4.3 North America Leiomyosarcoma Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Leiomyosarcoma Drug Sales by Company
7.1.1 Europe Leiomyosarcoma Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Leiomyosarcoma Drug Revenue by Company (2018-2023)
7.2 Europe Leiomyosarcoma Drug Market Size by Type
7.2.1 Europe Leiomyosarcoma Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Leiomyosarcoma Drug Revenue by Type (2018-2034)
7.3 Europe Leiomyosarcoma Drug Market Size by Application
7.3.1 Europe Leiomyosarcoma Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Leiomyosarcoma Drug Revenue by Application (2018-2034)
7.4 Europe Leiomyosarcoma Drug Market Size by Country
7.4.1 Europe Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Leiomyosarcoma Drug Revenue by Country (2018-2034)
7.4.3 Europe Leiomyosarcoma Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Leiomyosarcoma Drug Sales by Company
8.1.1 China Leiomyosarcoma Drug Sales Quantity by Company (2018-2023)
8.1.2 China Leiomyosarcoma Drug Revenue by Company (2018-2023)
8.2 China Leiomyosarcoma Drug Market Size by Type
8.2.1 China Leiomyosarcoma Drug Sales Quantity by Type (2018-2034)
8.2.2 China Leiomyosarcoma Drug Revenue by Type (2018-2034)
8.3 China Leiomyosarcoma Drug Market Size by Application
8.3.1 China Leiomyosarcoma Drug Sales Quantity by Application (2018-2034)
8.3.2 China Leiomyosarcoma Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Leiomyosarcoma Drug Sales by Company
9.1.1 APAC Leiomyosarcoma Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Leiomyosarcoma Drug Revenue by Company (2018-2023)
9.2 APAC Leiomyosarcoma Drug Market Size by Type
9.2.1 APAC Leiomyosarcoma Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Leiomyosarcoma Drug Revenue by Type (2018-2034)
9.3 APAC Leiomyosarcoma Drug Market Size by Application
9.3.1 APAC Leiomyosarcoma Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Leiomyosarcoma Drug Revenue by Application (2018-2034)
9.4 APAC Leiomyosarcoma Drug Market Size by Region
9.4.1 APAC Leiomyosarcoma Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Leiomyosarcoma Drug Revenue by Region (2018-2034)
9.4.3 APAC Leiomyosarcoma Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Leiomyosarcoma Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Leiomyosarcoma Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Leiomyosarcoma Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Leiomyosarcoma Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Advenchen Laboratories, LLC
11.1.1 Advenchen Laboratories, LLC Company Information
11.1.2 Advenchen Laboratories, LLC Overview
11.1.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Products and Services
11.1.5 Advenchen Laboratories, LLC Leiomyosarcoma Drug SWOT Analysis
11.1.6 Advenchen Laboratories, LLC Recent Developments
11.2 BeiGene, Ltd.
11.2.1 BeiGene, Ltd. Company Information
11.2.2 BeiGene, Ltd. Overview
11.2.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 BeiGene, Ltd. Leiomyosarcoma Drug Products and Services
11.2.5 BeiGene, Ltd. Leiomyosarcoma Drug SWOT Analysis
11.2.6 BeiGene, Ltd. Recent Developments
11.3 Cell Medica Limited
11.3.1 Cell Medica Limited Company Information
11.3.2 Cell Medica Limited Overview
11.3.3 Cell Medica Limited Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Cell Medica Limited Leiomyosarcoma Drug Products and Services
11.3.5 Cell Medica Limited Leiomyosarcoma Drug SWOT Analysis
11.3.6 Cell Medica Limited Recent Developments
11.4 Karyopharm Therapeutics, Inc.
11.4.1 Karyopharm Therapeutics, Inc. Company Information
11.4.2 Karyopharm Therapeutics, Inc. Overview
11.4.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Products and Services
11.4.5 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug SWOT Analysis
11.4.6 Karyopharm Therapeutics, Inc. Recent Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Information
11.5.2 Merck & Co., Inc. Overview
11.5.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Merck & Co., Inc. Leiomyosarcoma Drug Products and Services
11.5.5 Merck & Co., Inc. Leiomyosarcoma Drug SWOT Analysis
11.5.6 Merck & Co., Inc. Recent Developments
11.6 Mirati Therapeutics Inc.
11.6.1 Mirati Therapeutics Inc. Company Information
11.6.2 Mirati Therapeutics Inc. Overview
11.6.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Products and Services
11.6.5 Mirati Therapeutics Inc. Leiomyosarcoma Drug SWOT Analysis
11.6.6 Mirati Therapeutics Inc. Recent Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Information
11.7.2 Novartis AG Overview
11.7.3 Novartis AG Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Novartis AG Leiomyosarcoma Drug Products and Services
11.7.5 Novartis AG Leiomyosarcoma Drug SWOT Analysis
11.7.6 Novartis AG Recent Developments
11.8 Vicore Pharma AB
11.8.1 Vicore Pharma AB Company Information
11.8.2 Vicore Pharma AB Overview
11.8.3 Vicore Pharma AB Leiomyosarcoma Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Vicore Pharma AB Leiomyosarcoma Drug Products and Services
11.8.5 Vicore Pharma AB Leiomyosarcoma Drug SWOT Analysis
11.8.6 Vicore Pharma AB Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Leiomyosarcoma Drug Value Chain Analysis
12.2 Leiomyosarcoma Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Leiomyosarcoma Drug Production Mode & Process
12.4 Leiomyosarcoma Drug Sales and Marketing
12.4.1 Leiomyosarcoma Drug Sales Channels
12.4.2 Leiomyosarcoma Drug Distributors
12.5 Leiomyosarcoma Drug Customers
13 Market Dynamics
13.1 Leiomyosarcoma Drug Industry Trends
13.2 Leiomyosarcoma Drug Market Drivers
13.3 Leiomyosarcoma Drug Market Challenges
13.4 Leiomyosarcoma Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of AL-3818
Table 3. Major Manufacturers of BGB-290
Table 4. Major Manufacturers of C-21
Table 5. Major Manufacturers of Others
Table 6. Global Leiomyosarcoma Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Leiomyosarcoma Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Leiomyosarcoma Drug Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Leiomyosarcoma Drug Revenue Market Share by Region (2018-2023)
Table 10. Global Leiomyosarcoma Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Leiomyosarcoma Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Leiomyosarcoma Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 13. Global Leiomyosarcoma Drug Sales by Region (2018-2023) & (K Pcs)
Table 14. Global Leiomyosarcoma Drug Sales Market Share by Region (2018-2023)
Table 15. Global Leiomyosarcoma Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Leiomyosarcoma Drug Sales Market Share by Region (2024-2034)
Table 17. Global Leiomyosarcoma Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 18. Global Leiomyosarcoma Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 19. Global Leiomyosarcoma Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global Leiomyosarcoma Drug Revenue Share by Manufacturers (2018-2023)
Table 21. Global Leiomyosarcoma Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 22. Global Key Players of Leiomyosarcoma Drug, Industry Ranking, 2021 VS 2024
Table 23. Global Leiomyosarcoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Leiomyosarcoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leiomyosarcoma Drug as of 2024)
Table 25. Global Key Manufacturers of Leiomyosarcoma Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Leiomyosarcoma Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Leiomyosarcoma Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 30. Global Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Leiomyosarcoma Drug Sales Quantity Share by Type (2018-2023)
Table 32. Global Leiomyosarcoma Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Leiomyosarcoma Drug Revenue Share by Type (2018-2023)
Table 36. Global Leiomyosarcoma Drug Revenue Share by Type (2024-2034)
Table 37. Leiomyosarcoma Drug Price by Type (2018-2023) & (USD/Pcs)
Table 38. Global Leiomyosarcoma Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 40. Global Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Leiomyosarcoma Drug Sales Quantity Share by Application (2018-2023)
Table 42. Global Leiomyosarcoma Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Leiomyosarcoma Drug Revenue Share by Application (2018-2023)
Table 46. Global Leiomyosarcoma Drug Revenue Share by Application (2024-2034)
Table 47. Leiomyosarcoma Drug Price by Application (2018-2023) & (USD/Pcs)
Table 48. Global Leiomyosarcoma Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Leiomyosarcoma Drug Revenue by Company (2018-2023) & (US$ Million)
Table 50. North America Leiomyosarcoma Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 51. North America Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 52. North America Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 54. North America Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 56. North America Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 58. North America Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 60. North America Leiomyosarcoma Drug Revenue by Country (2018-2023) & (US$ Million)
Table 61. North America Leiomyosarcoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Leiomyosarcoma Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 63. North America Leiomyosarcoma Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Leiomyosarcoma Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 65. Europe Leiomyosarcoma Drug Revenue by Company (2018-2023) & (US$ Million)
Table 66. Europe Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 67. Europe Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 69. Europe Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 71. Europe Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 73. Europe Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 75. Europe Leiomyosarcoma Drug Revenue by Country (2018-2023) & (US$ Million)
Table 76. Europe Leiomyosarcoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Leiomyosarcoma Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 78. Europe Leiomyosarcoma Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Leiomyosarcoma Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 80. China Leiomyosarcoma Drug Revenue by Company (2018-2023) & (US$ Million)
Table 81. China Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 82. China Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 84. China Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 86. China Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 88. China Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Leiomyosarcoma Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 90. APAC Leiomyosarcoma Drug Revenue by Company (2018-2023) & (US$ Million)
Table 91. APAC Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 92. APAC Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 94. APAC Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 96. APAC Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 98. APAC Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Leiomyosarcoma Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 100. APAC Leiomyosarcoma Drug Revenue by Region (2018-2023) & (US$ Million)
Table 101. APAC Leiomyosarcoma Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Leiomyosarcoma Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 103. APAC Leiomyosarcoma Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 105. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Company (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Type (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 111. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Application (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Country (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 118. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Advenchen Laboratories, LLC Company Information
Table 120. Advenchen Laboratories, LLC Description and Overview
Table 121. Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 122. Advenchen Laboratories, LLC Leiomyosarcoma Drug Product and Services
Table 123. Advenchen Laboratories, LLC Leiomyosarcoma Drug SWOT Analysis
Table 124. Advenchen Laboratories, LLC Recent Developments
Table 125. BeiGene, Ltd. Company Information
Table 126. BeiGene, Ltd. Description and Overview
Table 127. BeiGene, Ltd. Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 128. BeiGene, Ltd. Leiomyosarcoma Drug Product and Services
Table 129. BeiGene, Ltd. Leiomyosarcoma Drug SWOT Analysis
Table 130. BeiGene, Ltd. Recent Developments
Table 131. Cell Medica Limited Company Information
Table 132. Cell Medica Limited Description and Overview
Table 133. Cell Medica Limited Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 134. Cell Medica Limited Leiomyosarcoma Drug Product and Services
Table 135. Cell Medica Limited Leiomyosarcoma Drug SWOT Analysis
Table 136. Cell Medica Limited Recent Developments
Table 137. Karyopharm Therapeutics, Inc. Company Information
Table 138. Karyopharm Therapeutics, Inc. Description and Overview
Table 139. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 140. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product and Services
Table 141. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug SWOT Analysis
Table 142. Karyopharm Therapeutics, Inc. Recent Developments
Table 143. Merck & Co., Inc. Company Information
Table 144. Merck & Co., Inc. Description and Overview
Table 145. Merck & Co., Inc. Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 146. Merck & Co., Inc. Leiomyosarcoma Drug Product and Services
Table 147. Merck & Co., Inc. Leiomyosarcoma Drug SWOT Analysis
Table 148. Merck & Co., Inc. Recent Developments
Table 149. Mirati Therapeutics Inc. Company Information
Table 150. Mirati Therapeutics Inc. Description and Overview
Table 151. Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 152. Mirati Therapeutics Inc. Leiomyosarcoma Drug Product and Services
Table 153. Mirati Therapeutics Inc. Leiomyosarcoma Drug SWOT Analysis
Table 154. Mirati Therapeutics Inc. Recent Developments
Table 155. Novartis AG Company Information
Table 156. Novartis AG Description and Overview
Table 157. Novartis AG Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 158. Novartis AG Leiomyosarcoma Drug Product and Services
Table 159. Novartis AG Leiomyosarcoma Drug SWOT Analysis
Table 160. Novartis AG Recent Developments
Table 161. Vicore Pharma AB Company Information
Table 162. Vicore Pharma AB Description and Overview
Table 163. Vicore Pharma AB Leiomyosarcoma Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 164. Vicore Pharma AB Leiomyosarcoma Drug Product and Services
Table 165. Vicore Pharma AB Leiomyosarcoma Drug SWOT Analysis
Table 166. Vicore Pharma AB Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Leiomyosarcoma Drug Distributors List
Table 170. Leiomyosarcoma Drug Customers List
Table 171. Leiomyosarcoma Drug Market Trends
Table 172. Leiomyosarcoma Drug Market Drivers
Table 173. Leiomyosarcoma Drug Market Challenges
Table 174. Leiomyosarcoma Drug Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Leiomyosarcoma Drug Product Picture
Figure 2. Global Leiomyosarcoma Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Leiomyosarcoma Drug Market Share by Type in 2024 & 2034
Figure 4. AL-3818 Product Picture
Figure 5. BGB-290 Product Picture
Figure 6. C-21 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Leiomyosarcoma Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 9. Global Leiomyosarcoma Drug Market Share by Application in 2024 & 2034
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Leiomyosarcoma Drug Report Years Considered
Figure 14. Global Leiomyosarcoma Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Leiomyosarcoma Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Leiomyosarcoma Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Leiomyosarcoma Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Leiomyosarcoma Drug Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Leiomyosarcoma Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Leiomyosarcoma Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Leiomyosarcoma Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Leiomyosarcoma Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Leiomyosarcoma Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Leiomyosarcoma Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Leiomyosarcoma Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Leiomyosarcoma Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Leiomyosarcoma Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Leiomyosarcoma Drug Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Leiomyosarcoma Drug Revenue in 2024
Figure 32. Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Leiomyosarcoma Drug Revenue Market Share by Company in 2024
Figure 38. North America Leiomyosarcoma Drug Sales Quantity Market Share by Company in 2024
Figure 39. North America Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Leiomyosarcoma Drug Revenue Share by Country (2018-2034)
Figure 44. North America Leiomyosarcoma Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Leiomyosarcoma Drug Sales Quantity Market Share by Company in 2024
Figure 48. Europe Leiomyosarcoma Drug Revenue Market Share by Company in 2024
Figure 49. Europe Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Leiomyosarcoma Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Leiomyosarcoma Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Leiomyosarcoma Drug Sales Quantity Market Share by Company in 2024
Figure 61. China Leiomyosarcoma Drug Revenue Market Share by Company in 2024
Figure 62. China Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Leiomyosarcoma Drug Sales Quantity Market Share by Company in 2024
Figure 67. APAC Leiomyosarcoma Drug Revenue Market Share by Company in 2024
Figure 68. APAC Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Leiomyosarcoma Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Leiomyosarcoma Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Leiomyosarcoma Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Leiomyosarcoma Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Leiomyosarcoma Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Leiomyosarcoma Drug Value Chain
Figure 93. Leiomyosarcoma Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed